Endogena is a biotech company that develops endogenous regenerative medicines to repair and regenerate tissues and organs.
Endogena has raised $21.0M in total funding. The most recent round was Series A. The last funding was announced in December 2021.
Endogena's investors include DEFTA Partners, Centenara Labs.
Endogena is headquartered in San Francisco, United States.
Endogena is a biotech company that develops endogenous regenerative medicines to repair and regenerate tissues and organs.
Endogena is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Endogena — Funding & Investors." VCBacked, December 13, 2021, https://www.vcbacked.co/company/endogena. Accessed November 17, 2026.
VCBacked. (2021). Endogena — Funding & Investors. Retrieved November 17, 2026, from https://www.vcbacked.co/company/endogena
{{cite web |title=Endogena — Funding & Investors |url=https://www.vcbacked.co/company/endogena |website=VCBacked |access-date=November 17, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Endogena? Request a listing update